Immune Profiling of Medullary Thyroid Cancer—An Opportunity for Immunotherapy
Medullary thyroid cancer (MTC) is a rare malignancy that arises from calcitonin-producing C-cells. Curative treatment for patients with metastatic MTC is challenging. Identifying the mechanisms by which cancer cells inhibit the activity of immune cells provides an opportunity to develop new therapie...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Genes |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4425/12/10/1534 |
| _version_ | 1797514498869821440 |
|---|---|
| author | Kinga Hińcza-Nowak Artur Kowalik Agnieszka Walczyk Iwona Pałyga Danuta Gąsior-Perczak Agnieszka Płusa Janusz Kopczyński Magdalena Chrapek Stanisław Góźdź Aldona Kowalska |
| author_facet | Kinga Hińcza-Nowak Artur Kowalik Agnieszka Walczyk Iwona Pałyga Danuta Gąsior-Perczak Agnieszka Płusa Janusz Kopczyński Magdalena Chrapek Stanisław Góźdź Aldona Kowalska |
| author_sort | Kinga Hińcza-Nowak |
| collection | DOAJ |
| description | Medullary thyroid cancer (MTC) is a rare malignancy that arises from calcitonin-producing C-cells. Curative treatment for patients with metastatic MTC is challenging. Identifying the mechanisms by which cancer cells inhibit the activity of immune cells provides an opportunity to develop new therapies that restore anticancer activity. Little is known about the immunological phenomena underlying MTC. Here, we examined the expression profile of 395 genes associated with MTC. The study included 51 patients diagnosed with MTC at a single center. Bioinformatical analysis revealed that CD276 expression in MTC cells was at least three-fold higher than that in normal tissue. The expression of CD276 showed a weak but statistically significant positive correlation with tumor diameter, but we did not find a significant association between CD276 expression and other histopathological clinical factors, or the response to initial therapy. A search of published data identified the monoclonal antibody (inhibitor) enoblituzumab as a potential drug for patients diagnosed with MTC overexpressing CD276. |
| first_indexed | 2024-03-10T06:32:29Z |
| format | Article |
| id | doaj.art-272dc10cb931467584d56ace55eaf11f |
| institution | Directory Open Access Journal |
| issn | 2073-4425 |
| language | English |
| last_indexed | 2024-03-10T06:32:29Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Genes |
| spelling | doaj.art-272dc10cb931467584d56ace55eaf11f2023-11-22T18:21:28ZengMDPI AGGenes2073-44252021-09-011210153410.3390/genes12101534Immune Profiling of Medullary Thyroid Cancer—An Opportunity for ImmunotherapyKinga Hińcza-Nowak0Artur Kowalik1Agnieszka Walczyk2Iwona Pałyga3Danuta Gąsior-Perczak4Agnieszka Płusa5Janusz Kopczyński6Magdalena Chrapek7Stanisław Góźdź8Aldona Kowalska9Department of Molecular Diagnostics, Holycross Cancer Centre, 25-734 Kielce, PolandDepartment of Molecular Diagnostics, Holycross Cancer Centre, 25-734 Kielce, PolandEndocrinology Clinic, Holycross Cancer Centre, 25-734 Kielce, PolandEndocrinology Clinic, Holycross Cancer Centre, 25-734 Kielce, PolandEndocrinology Clinic, Holycross Cancer Centre, 25-734 Kielce, PolandSurgical Pathology, Holycross Cancer Centre, 25-734 Kielce, PolandSurgical Pathology, Holycross Cancer Centre, 25-734 Kielce, PolandFaculty of Natural Sciences, Jan Kochanowski University, 25-406 Kielce, PolandCollegium Medicum, Jan Kochanowski University, 25-319 Kielce, PolandEndocrinology Clinic, Holycross Cancer Centre, 25-734 Kielce, PolandMedullary thyroid cancer (MTC) is a rare malignancy that arises from calcitonin-producing C-cells. Curative treatment for patients with metastatic MTC is challenging. Identifying the mechanisms by which cancer cells inhibit the activity of immune cells provides an opportunity to develop new therapies that restore anticancer activity. Little is known about the immunological phenomena underlying MTC. Here, we examined the expression profile of 395 genes associated with MTC. The study included 51 patients diagnosed with MTC at a single center. Bioinformatical analysis revealed that CD276 expression in MTC cells was at least three-fold higher than that in normal tissue. The expression of CD276 showed a weak but statistically significant positive correlation with tumor diameter, but we did not find a significant association between CD276 expression and other histopathological clinical factors, or the response to initial therapy. A search of published data identified the monoclonal antibody (inhibitor) enoblituzumab as a potential drug for patients diagnosed with MTC overexpressing CD276.https://www.mdpi.com/2073-4425/12/10/1534medullary thyroid cancerimmunotherapyCD276 |
| spellingShingle | Kinga Hińcza-Nowak Artur Kowalik Agnieszka Walczyk Iwona Pałyga Danuta Gąsior-Perczak Agnieszka Płusa Janusz Kopczyński Magdalena Chrapek Stanisław Góźdź Aldona Kowalska Immune Profiling of Medullary Thyroid Cancer—An Opportunity for Immunotherapy Genes medullary thyroid cancer immunotherapy CD276 |
| title | Immune Profiling of Medullary Thyroid Cancer—An Opportunity for Immunotherapy |
| title_full | Immune Profiling of Medullary Thyroid Cancer—An Opportunity for Immunotherapy |
| title_fullStr | Immune Profiling of Medullary Thyroid Cancer—An Opportunity for Immunotherapy |
| title_full_unstemmed | Immune Profiling of Medullary Thyroid Cancer—An Opportunity for Immunotherapy |
| title_short | Immune Profiling of Medullary Thyroid Cancer—An Opportunity for Immunotherapy |
| title_sort | immune profiling of medullary thyroid cancer an opportunity for immunotherapy |
| topic | medullary thyroid cancer immunotherapy CD276 |
| url | https://www.mdpi.com/2073-4425/12/10/1534 |
| work_keys_str_mv | AT kingahinczanowak immuneprofilingofmedullarythyroidcanceranopportunityforimmunotherapy AT arturkowalik immuneprofilingofmedullarythyroidcanceranopportunityforimmunotherapy AT agnieszkawalczyk immuneprofilingofmedullarythyroidcanceranopportunityforimmunotherapy AT iwonapałyga immuneprofilingofmedullarythyroidcanceranopportunityforimmunotherapy AT danutagasiorperczak immuneprofilingofmedullarythyroidcanceranopportunityforimmunotherapy AT agnieszkapłusa immuneprofilingofmedullarythyroidcanceranopportunityforimmunotherapy AT januszkopczynski immuneprofilingofmedullarythyroidcanceranopportunityforimmunotherapy AT magdalenachrapek immuneprofilingofmedullarythyroidcanceranopportunityforimmunotherapy AT stanisławgozdz immuneprofilingofmedullarythyroidcanceranopportunityforimmunotherapy AT aldonakowalska immuneprofilingofmedullarythyroidcanceranopportunityforimmunotherapy |